American Journal of Roentgenology · 2012 · 44 citations · 10 references
MedicineOncologyRadiologyCancer Drug Toxicity ManagementGastrointestinal OncologyMolecular OncologyAbdominal ImagingAbdominal Oncology ImagingAbdominal RadiologyCancer Molecular PathologyHepatobiliary ImagingToxicity ManagementEarly DiagnosisMolecularly Targeted AgentsTargeted Molecular Imaging AgentsTargeted Molecular TherapyTargeted Therapy HepatotoxicityTargeted Therapy ToxicityTargeted Therapy-related Gastrointestinal ToxicityTherapeutic Response Monitoring
OBJECTIVE: Novel drugs targeting molecular pathways involved in tumor development have revolutionized cancer treatment. Radiologists often focus on therapeutic response when evaluating cancer patients and may miss important signs of drug toxicity. This article familiarizes radiologists with the complications of molecular targeted agents in abdominal solid organs, enabling early identification and appropriate intervention and thus reducing patient morbidity and mortality. CONCLUSION: Knowledge of the common abdominal toxicities--including hepatitis, cholecystitis, pancreatitis, fluid retention, and infection--is crucial for early diagnosis, which may spare patients devastating complications or the need for surgery.
10
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
Martin H. Cohen, John R. Johnson, Yeh‐Fong Chen et al. · The Oncologist · 2005 · 441 citations
Medicine, Oncology, Pharmacology +14
M. van Glabbeke, Jaap Verweij, Paolo G. Casali et al. · European Journal of Cancer · 2006 · 102 citations
Pharmacy, Oncology, Pharmacology +12
Fulminant Hepatic Failure Secondary to Erlotinib
Weitian Liu, Frederick L. Makrauer, Amir Qamar et al. · Clinical Gastroenterology and Hepatology · 2007 · 37 citations
Medicine, Oncology, Pharmacotherapy +10